Drug-induced long QT and torsade de pointes: recent advances.
Kannankeril PJ, Roden DM.
Curr Opin Cardiol. 2007 Jan;22(1):39-43. doi: 10.1097/HCO.0b013e32801129eb.
Drug-induced QT Interval Prolongation in the Intensive Care Unit.
Etchegoyen CV, Keller GA, Mrad S, Cheng S, Di Girolamo G.
Curr Clin Pharmacol. 2017;12(4):210-222. doi: 10.2174/1574884713666180223123947.
Drug-induced torsade de pointes. Incidence, management and prevention.
Faber TS, Zehender M, Just H.
Drug Saf. 1994 Dec;11(6):463-76. doi: 10.2165/00002018-199411060-00007.
Managing drug-induced QT prolongation in clinical practice.
Khatib R, Sabir FRN, Omari C, Pepper C, Tayebjee MH.
Postgrad Med J. 2021 Jul;97(1149):452-458. doi: 10.1136/postgradmedj-2020-138661. Epub 2020 Oct 29.
Drug-induced long QT syndrome and torsade de pointes.
Morissette P, Hreiche R, Turgeon J.
Can J Cardiol. 2005 Aug;21(10):857-64.
Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.
Jackobson G, Carmel NN, Lotan D, Kremer A, Justo D.
Z Gerontol Geriatr. 2018 Jan;51(1):41-47. doi: 10.1007/s00391-016-1155-5. Epub 2016 Nov 22.
Seizure-induced Torsades de pointes:In a canine drug-induced long-QT1 model.
van der Linde H, Kreir M, Teisman A, Gallacher DJ.
J Pharmacol Toxicol Methods. 2021 Sep-Oct;111:107086. doi: 10.1016/j.vascn.2021.107086. Epub 2021 Jun 10.
Drug-induced torsade de pointes: from molecular biology to bedside.
Tamargo J.
Jpn J Pharmacol. 2000 May;83(1):1-19. doi: 10.1254/jjp.83.1.
Predicting drug-induced QT prolongation and torsades de pointes.
Roden DM.
J Physiol. 2016 May 1;594(9):2459-68. doi: 10.1113/JP270526. Epub 2016 Jan 18.
Assessing predictors of drug-induced torsade de pointes.
Belardinelli L, Antzelevitch C, Vos MA.
Trends Pharmacol Sci. 2003 Dec;24(12):619-25. doi: 10.1016/j.tips.2003.10.002.
